EUVIMEDEUVIMED entdecken
Open Access

Utilization of Colonoscopy Following Treatment Initiation in U.S. Commercially Insured Patients With Inflammatory Bowel Disease, 2013-2019

Jeff Y Yang iD, Jennifer L Lund, Virginia Pate, Michael D Kappelman

Inflammatory Bowel Diseases · 02.05.2023 · 29 (5) · 735-743

DOI: 10.1093/ibd/izac136 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 05.08.2022. Verfasst von Jeff Y Yang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NIDDK NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Evaluation of mucosal healing with colonoscopy is recommended for inflammatory bowel disease (IBD) management; however, little is known about real-world use of treat-to-target monitoring following IBD treatment initiation. We aimed to estimate the proportion of U.S. commercially insured IBD patients who receive colonoscopy in the 3 to 15 months after initiating treatment.

Methods

We identified IBD patients, 18 to 64 years of age, in the IBM MarketScan Commercial Claims and Encounters database as those with ≥3 IBD diagnoses prior to initiation of biologic, small molecule, or immunomodulatory treatment. We excluded patients with prior colectomy and with rheumatologic and other indications for these therapies. Colonoscopies were identified using International Classification of Diseases–Ninth Revision, International Classification of Diseases–Tenth Revision, and Current Procedural Terminology procedure codes. We used Kaplan-Meier methods to estimate the proportion of newly treated IBD patients who received colonoscopy in the 3 to 6 months, 3 to 12 months, and 3 to 15 months following treatment initiation, and stratified trends by year, patient age and sex, and region.

Results

From 2013 to 2019, we identified 39 734 initiators of IBD medications (51.9% female, mean age 39.4 years). We observed similar colonoscopy incidence among ulcerative colitis patients (3-6 months: 14.2% [95% confidence interval (CI), 13.6%-14.8%]; 3-12 months: 37.7% [95% CI, 36.8%-38.6%]; 3-15 months: 46.1% [95% CI, 45.2%-47.1%]) and Crohn’s disease patients (3-6 months: 11.2% [95% CI, 10.8%-11.6%]; 3-12 months: 32.2% [95% CI, 31.5%-32.9%]; 3-15 months: CD: 40.1% [95% CI, 39.3%-40.8%]). Overall colonoscopy use was slightly higher among women, patients in the Northeast, and those initiating newer biologic therapies.

Conclusions

Fewer than half of newly treated IBD patients underwent colonoscopy within 3 to 15 months of initiating new treatment, suggesting low uptake of treat-to-target endoscopic disease monitoring in real-world practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesColitis, UlcerativeCrohn DiseaseHumansFemaleAdultMaleColonoscopy

Stichwörter der Autor:innen

MarketScan claimscolonoscopyinflammatory bowel diseasepharmacoepidemiologytreat to target

Autor:innen und Institutionen

  • Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Division of Pediatric Gastroenterology, Department of Pediatrics, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

ORCID-Profile: Jeff Y Yang

Förderung

  • NCATS NIH HHS
  • NIDDK NIH HHS
  • NIH HHS
  • National Institutes of Health
  • University of North Carolina at Chapel Hill
  • Royster Society of Fellows
  • Center for Pharmacoepidemiology
  • Department of Epidemiology

Zitieren

APA

Yang, J. Y., Lund, J. L., Pate, V., & Kappelman, M. D. (2023). Utilization of Colonoscopy Following Treatment Initiation in U.S. Commercially Insured Patients With Inflammatory Bowel Disease, 2013-2019. Inflammatory Bowel Diseases, 29(5), 735-743. https://doi.org/10.1093/ibd/izac136

Vancouver

Yang JY, Lund JL, Pate V, Kappelman MD. Utilization of Colonoscopy Following Treatment Initiation in U.S. Commercially Insured Patients With Inflammatory Bowel Disease, 2013-2019. Inflammatory Bowel Diseases. 2023;29(5):735-743. doi:10.1093/ibd/izac136

BibTeX
@article{Yang2023,
  author = {Yang, Jeff Y and Lund, Jennifer L and Pate, Virginia and Kappelman, Michael D},
  title = {Utilization of Colonoscopy Following Treatment Initiation in U.S. Commercially Insured Patients With Inflammatory Bowel Disease, 2013-2019},
  journal = {Inflammatory Bowel Diseases},
  year = {2023},
  volume = {29},
  number = {5},
  pages = {735--743},
  doi = {10.1093/ibd/izac136}
}
Kostenlos starten →